Newsletter Subject

A Woman Was Accused of Murder After Losing Her Pregnancy. Now She Tells Her Story.

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Sat, Oct 5, 2024 11:14 AM

Email Preheader Text

Weekly Review Saturday, October 05, 2024 THE BREAK ROOM CME SPOTLIGHT THE BREAK ROOM ADVERTISEMENT C

[MEDPAGE TODAY]( Weekly Review Saturday, October 05, 2024 [A Woman Was Accused of Murder After Losing Her Pregnancy. Now She Tells Her Story.]( [Witnesses in OR Give Harrowing Account of Spleen Surgery Gone Wrong]( [Therapist's Grisly Death; Surgery Center Wins $421M; Army Doc's Plea Deal]( THE BREAK ROOM [Wordectomy: Guess Today’s Medical Condition]( CME SPOTLIGHT [Exploring HER2 Targeting: Transforming Treatment for Metastatic and Locally Advanced HER2+ Cancers]( [Falling May Be a Harbinger of Dementia in Older Adults]( [As #Mouthtape for Sleep Apnea Takes Off, Research Raises Concern for One Group]( THE BREAK ROOM [Play Today's Wordosis: Our Medical Word Game]( ADVERTISEMENT [Psychiatric Hospital Chain's Charges; Schizophrenia Drug Flops; Bright Light Therapy]( CME SPOTLIGHT [Precision Targeting in Acute Myeloid Leukemia: Optimizing Disease-Informed, Patient-Centered Care]( [Study Finds More Heart Defects in Kids Conceived With ART]( [Reclaiming the Night in the Wake of 'Abhaya's' Murder]( [Drug-Free Obesity Capsule Cleared; FDA Reviews Acromegaly Tx; Stem Cells Reverse T1D]( CME SPOTLIGHT [Breakthrough Immunotherapies Transforming Early-Stage NSCLC Treatment]( [In Diagnosing Knee Pain, Sometimes More Is More]( [Low-Dose Lithium Tested in Long COVID]( [The Disease of Nine Months: Caring for Women Before and After Roe]( CME SPOTLIGHT [Harnessing the Power of Immuno-Modulating Vaccines in Cancer Treatment]( [Doctors Cut Back on Seeing Medicare Patients as Another Pay Cut Looms]( [Metabolic Accelerator Shows Promise for Weight Loss Side of Obesity-HFpEF Equation]( [Hearing Loss-Cognition Link; Circadian Brain Changes; Repetitive Head Impact Markers]( CME SPOTLIGHT [Optimizing Use of PARP Inhibitors in Early-Stage and Metastatic Breast Cancer Patients With DNA Damage Repair Pathway Mutations]( [Happy People, Happy Hearts? Ultra-Processed Foods and Diabetes Risk]( [Can HPV Self-Tests Truly Replace Pap Smears?]( [In a First, Academic Center Offers Chiropractic Program]( CME SPOTLIGHT [Changing Inertia in Chronic Myeloid Leukemia Management: Key Strategies From Leading Experts]( [Judge Rules Against Stem Cell Clinic]( [Best VP Debate Memes; 'Terrifying' AI Study Tool; MD's Mental Health Playlist]( [Conversion Practices Tied to Greater Symptoms of PTSD, Suicidality]( CME SPOTLIGHT [Decoding Complex Chronic Lymphocytic Leukemia Cases: An Expert TheraTalk]( [Social Media Trend Promotes Nitrous Oxide Misuse]( [Ob/Gyn Applications Stable in First Year of Independent Residency System]( [Good News for CAR-T Therapy; Liquid Biopsy Progress; Anti-Psychotic for Brain Cancer]( CME SPOTLIGHT [Treatment Crossroads: Diverse Perspectives on Treatment Strategies for Relapsed/Refractory DLBCL and FL]( [Medicare Part D, Medicare Advantage Plan Premiums to Stay Stable in 2025, CMS Says]( [Bans on High-Capacity Magazines Tied to 91% Drop in Child Deaths in Mass Shootings]( ['Nursing Isn't for You': What We Heard This Week]( [Vaccines and Long COVID: What Do We Know?]( Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. [SEE ALL STORIES >]( Got a news tip? MedPage Today offers several ways to provide information to our journalists securely and confidentially. [LEARN MORE >]( [EVERYDAY HEALTH]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_DHE_Weekly?xid=nl_mpt_DHE_2024-10-05&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.